PD-1 and PD-L1 Inhibitors Competitive Landscape, Pipeline and Market Analysis 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017" report to their offering.

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

This report assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Scope:

  • The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for PD and PD-L1 inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
  • The report also gives the information of dormant pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Introduction
  2. Executive Summary
  3. Programmed Death 1 (PD-1)
  4. Programmed Death Ligand 1 (PD-L1)
  5. Role of PD-1 and PD-L1 pathways
  6. MOA of PD-1 and PD-L1 inhibitors
  7. Significance of PD-1 and PD-L1 inhibitors
  8. PD-1 and PD-L1 Active Therapy Areas & Epidemiology
  9. Metastatic Renal Cell Carcinoma
  10. Squamous Cell Carcinomas of the Head and Neck
  11. Metastatic Colorectal Cancer
  12. Non-Small Cell lung cancer
  13. Biomarkers - PD-1 and PD-L1 inhibitors
  14. Market Overview
  15. Comparative Analysis of Pipeline &Marketed Drugs
  16. Marketed Product of PD-1 and PD-L1 drugs -Overview
  17. Marketed Drug Candidate Profiles
  • Pembrolizumab
  • Nivolumab
  • Atezolizumab

For more information about this report visit http://www.researchandmarkets.com/research/t9jfgg/pd1_and_pdl1

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs